Translate this page into:
Letter to the Editor
doi:
10.4103/sajc.sajc_400_18
Severe hypoglycemia with trastuzumab: An unseen adverse event
1
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
*Corresponding author: Dr. Parveen Jain. drparveen1010@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Hudis CA. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
- FDA Label-Trastuzumab. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf. [Last accessed on 2018 Nov 15].
- Herceptin and Hypoglycemia – From FDA Reports, eHealthME; November, 2018. Available from: https://www.ehealthme.com/ds/herceptin/hypoglycemia. [Last accessed on 2018 Nov 15].